USP7 and inflammatory bowel disease: Although NRF2 overactivation can also exacerbate colitis,[57] we found that the USP7 inhibitor P5091 relieved oxidative stress and attenuated gut inflammation in a DSS‐induced colitis mouse model, suggesting the clinical translation of USP7 inhibitors for IBD treatment.